Singletary S Eva, Connolly James L
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1. doi: 10.3322/canjclin.56.1.37.
The sixth edition of the AJCC Cancer Staging Manual contains some of the most extensive and significant revisions that have ever been made in the breast cancer staging system. The principal changes are related to the size, number, location, and method of detection of regional metastases to the lymph nodes. Some changes are related to the growing use of new technology (eg, sentinel lymph node biopsy, immunohistochemical staining, reverse transcriptase-polymerase chain reaction), whereas others are amendments of prior staging criteria, reflecting recent clinical evidence or widespread clinical consensus. Available data did not support the addition of new prognostic indicators such as histologic tumor grade to the tumor-node-metastasis system at this time. Future developments in determining breast cancer prognosis will most likely incorporate new approaches to identifying the genetic fingerprint of individual tumors.
美国癌症联合委员会(AJCC)《癌症分期手册》第六版对乳腺癌分期系统进行了一些最为广泛且重大的修订。主要变化涉及区域淋巴结转移的大小、数量、位置及检测方法。部分变化与新技术(如前哨淋巴结活检、免疫组化染色、逆转录聚合酶链反应)的日益广泛应用有关,而其他变化则是对先前分期标准的修正,反映了近期的临床证据或广泛的临床共识。现有数据目前并不支持在肿瘤-淋巴结-转移系统中增加新的预后指标,如组织学肿瘤分级。确定乳腺癌预后的未来发展很可能会纳入识别个体肿瘤基因特征的新方法。